Aromatase inhibitors of the third generation in endocrine therapy of breast cancer and endometrial cancer: the successes and failures of the combination therapy

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review provides the current evidence of clinical studies on the effectiveness of endocrine therapy for breast cancer and endometrial cancer, including endometrial stromal sarcoma, by aromatase inhibitor (AI) III generation. The review presents dates from clinical trials comparing the effectiveness of AI and tamoxifen, as well as dates on combination therapy AI with inhibitors of mTOR pathway (BOLERO-2 trial), an antiestrogen (SWOG S0226, FACT, FIRST trials), an inhibitor of CDK4 / 6 (PALOMA -1 trial) and other drugs.

Full Text

Restricted Access

About the authors

Ekaterina P Fadeeva

St Petersburg City Clinical Oncology Dispensary

Author for correspondence.
Email: tapnatalia@yandex.ru
oncologist

Alla S Lisyanskaya

St Petersburg City Clinical Oncology Dispensary

Email: tapnatalia@yandex.ru
Ph.D. (Oncology)

Georgiy M Manikhas

St Petersburg City Clinical Oncology Dispensary

Email: tapnatalia@yandex.ru
Chief doctor

Ruslan I Glushakov

St Petersburg State Pediatric Medical University

Email: glushakovruslan@gmail.com
Ph.D. (Oncology), assistant Professor

Natalia I Tapilskaya

St Petersburg State Pediatric Medical University

Email: tapnatalia@yandex.ru
Dr. Med. Sci. (Obstetrics and Gynecology), Professor, Dept. of Obstetrics and Gynecology

References

  1. Состояние онкологической помощи населению России в 2013 году / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. - М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. - 235 с. [The state of cancer care to the population of Russia in 2014. Ed by V.I. Chissov, V.V. Starinsky, G.V. Petrova. Moscow: FGBU “MNIOI imeni P.A. Gertzena” Ministry of Health of Russia; 2014. 235 p. (In Russ).]
  2. Gunderson CC, Java J, Moore KN, Walker JL. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014;133(1):23-7. doi: 10.1016/j.ygyno.2014.01.041.
  3. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105-43. doi: 10.1016/S0020-7292(06)60031-3.
  4. Ballard KS, Homesley HD, Hodson C, et al. Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. J Gynecol Oncol. 2010;21(1):45-9. doi: 10.3802/jgo.2010.21.1.45.
  5. Бохман Я.В. Руководство по онкогинекологии. - СПб.: Фолиант, 2002. - 542 с. [Bokhman IV. Lectures on oncogynecology. Saint Petersburg: Foliant Publishers; 2002. 542 p. (In Russ).]
  6. Ruan AJ, Susil B, Jobling TW, Oehler MK. Endomertial cancer. Cell Tissue Res. 2005;322(1):53-61. doi: 10.1007/s00441-005-1109-5.
  7. Huang B, Warner M, Gustafsson JА. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015;418 Pt 3:240-4. doi: 10.1016/j.mce.2014.11.015.
  8. Chlebowski RT, Haque R, Hedlin H, et al. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015;154(3):609-16. doi: 10.1007/s10549-015-3647-1.
  9. Tseng L, Mazella J, Mann WJ. Estrogen synthesis in normal and malignant human endometrium. J Clin Endocronol Metab.1982;55(5):1029-31. doi: 10.1210/jcem-55-5-1029.
  10. Jongen VHWM, Thjssen JHH, Hollema H, et al. Is aromatase P450 involved in the patogenesis of endometrioid endometrial cancer? Int J Gynecol Cancer. 2005;15(3):529-36. doi: 10.1111/j.1525-1438.2005.15320.x.
  11. Лисянская А.С., Манихас Г.М., Шушания М.С., и др. Применение ингибитора ароматазы IІI поколения веро-анастрозола в качестве гормонотерапии рецидивирующего эпителиального рака яичника // Медицинский алфавит. - 2011. - Т. 4. - № 20. - С. 16-20. [Lisyanskaya AS, Manikhas GM, Shushanija MS, et al. Endocrine therapy of recurrent epithelial ovarian cancer by aromatase inhibitor IІI generation vero-anastrozole. Medicinskij alfavit. 2011;4(20):16-20. (In Russ).]
  12. Лисянская А.С., Тапильская Н.И., Манихас Г.М. Применение ингибиторов ароматазы третьего поколения в лечении рака эндометрия // Обзоры по клинической фармакологии и лекарственной терапии. - 2007. - Т. 5. - № 2. - С. 34-42. [Lisyanskaya AS, Tapilskaya NI, Manikhas GM. Endocrine therapy of endometrial cancer using aromatase inhibitor IІI generation. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii. 2007;5(2):34-42. (In Russ).]
  13. Лисянская А.С., Манихас Г.М., Тапильская Н.И., Федосенко К.В. Эндокринная терапия эндометриальной стромальной саркомы // Обзоры по клинической фармакологии и лекарственной терапии. - 2011. - Т. 9. - № 4. - С. 23-28. [Lisyanskaya AS, Manikhas GM, Tapilskaya NI, et al. Endocrine therapy of endometrial stromal sarcoma. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii. 2011;9 (4):23-28. (In Russ).]
  14. Santen RJ, Brodie H, Simpson ER, et al. History of aromatase: saga of an important biologic mediator and therapeutic target. Endocr Rev. 2009;30(4):343-75. doi: 10.1210/er.2008-0016.
  15. Lintermans A, Neven P. Safety of aromatase inhibitor therapy in breast cancer. Expert Opin Drug Saf. 2015;14(8):1201-11. doi: 10.1517/14740338.2015.1053458.
  16. Артамонова Е.В., Горбунова В.А., Жуков Н.В., и др. Трудности в лечении больных раком молочной железы в России: резолюция по итогам экспертного совета // Современная онкология. - 2014. - Т. 16. - № 2. - С. 12-16. [Artamonova EV, Gorbunova VA, Zhukov NV, et al. Difficulties in treating patients with breast cancer in russia: the resolution on the results of the review board. Sovremennaya onkologiya. 2014;16(2):12-17. (In Russ.)]
  17. Carlini P, Michelotti A, Ferretti G, et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest. 2007;25:102-5. doi: 10.1080/07357900701224789.
  18. Bria E, Ciccarese M, Giannarelli D, et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled analysis of 8794 patients. Cancer Treat Rev. 2006;32:325-32. doi: 10.1016/j.ctrv.2006.04.009
  19. Dowsett M, Forbes JF, Bradley R, et al. (Early Breast Cancer Trialists’ Collaborative Group). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1.
  20. Brower V. Aromatase inhibitors may reduce endometrial cancer risk. Lancet Oncol. 2015;16(4):e164. doi: 10.1016/S1470-2045(15)70119-1. doi: 10.1016/S1470-2045(15)70119-1.
  21. Duffy S, Jackson TL, Lansdown M, et. al. The ATAC (Arimidex, Tamoxifen alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod. 2006;21(2):545-53. doi: 10.1093/humrep/dei322.
  22. Garrone O, Bertelli G, Principe E, et al. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer. Tumori. 2014;100(6):620-4. doi: 10.1700/1778.19264.
  23. Лисянская А., Манихас Г., Фадеева Е., и др. Неоадъювантное применение ингибитора ароматазы веро-анастрозола в лечении рака эндометрия // Врач. - 2010. - № 11. - С. 15-17. [Lisyanskaya AS, Manikhas GM, Fadeeva EP, et al. Neoadjuvant use of the aromatase inhibitor vero-anastrosol in the treatment of endometrial cancer. Vrach. 2010;11:15-17. (In Russ.)]
  24. Лисянская А.С., Манихас Г.М., Тапильская Н.И., и др. Противоопухолевый эффект ингибитора ароматазы анастрозола на эндометрий у пациенток, получавших препарат в качестве неоадъювантной терапии рака тела матки // Ученые записки СПбГМУ им. акад. И.П. Павлова. - 2010. - Т. XVII. - № 3. - С. 37-39. [Lisyanskaya AS, Manikhas GM, Tapilskaya NI, et al. Anti-tumor effect of aromatase inhibitor anastrosole on endometrium in patients receiving the medicine as a neoadjuvant therapy for endometrium cancer. Uchenye zapiski SPbGMU imeni akademika I.P. Pavlova. 2010;17(3):37-39. (In Russ.)]
  25. Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78(2):212-6. doi: 10.1006/gyno.2000.5865.
  26. Battista MJ, Schmidt M, Eichbaum M, et al. Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch Gynecol Obstet. 2015;292(6):1355-60. doi: 10.1007/s00404-015-3786-y.
  27. Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14(4):650-8. doi: 10.1111/j.1048-891X.2004.14419.x.
  28. Берштейн Л.М., Чернобровкина А.Е., Гамаюнова В.Б. Активность ароматазы, тканевое содержание эстрогенов и особенности течения рака тела матки // Вопр. онкол. - 2003. - Т. 49. - № 2. - С. 55-59. [Berstein LM, Chernobrovkina AYe, Gamayunova VB, et al. Aromatase levels, estrogen concentration in tumor versus course of endometrial cancer. Voprosy onkologii. 2003;49(2):55-59. (In Russ.)]
  29. Berstein L, Zimarina T, Kovalevskij A, Maximov S. CYP19 gene expression and aromatase activity in endometiral cancer tissue: importance of the type of disease. Neoplasma. 2005;52(2):115-8.
  30. Yamaguchi M, Erdenebaatar C, Saito F, et al. Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in patients with advanced low-gradeendometrial stromal sarcoma. Int J Gynecol Cancer. 2015;25(9):1645-51. doi: 10.1097/IGC.0000000000000557.
  31. Yamazaki H, Todo Y, Mitsube K, et al. Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study. J Gynecol Oncol. 2015;26(3):214-21. doi: 10.3802/jgo.2015.26.3.214.
  32. Maluf FC, Sabbatini P, Schwartz L, et al. Endomertial Stromal Sarcoma: Objective response to letrozole. Gynecol Oncol. 2001;82(2):384-8. doi: 10.1006/gyno.2001.6238.
  33. Лисянская А.С., Манихас Г.М., Фадеева Е.П., и др. Эндометриальная стромальная саркома: полный ответ на терапию ингибитором ароматазы анастрозолом // Вопросы онкологии. - 2010. - Т. 56. - № 1. - С. 91-93. [Lisianskaia AS, Manikhas GM, Fadeeva EP, et al. Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole. Voprosy onkologii. 2010;56(1):91-3. (In Russ.)]
  34. Глушаков Р.И., Прошин С.Н., Тапильская Н.И. Роль тиреоидных гормонов в регуляции ангиогенеза, клеточной пролиферации и миграции // Гены и клетки. - 2011. - Т. 6. - № 4. - С. 26-33. [Glushakov RI, Proshin SN, Tapilskaya NI. The role of thyroid hormones in the regulation of the angiogenesis and cells proliferations. Geny i kletki. 2011;6(4):26-33].
  35. Zanardi E, Bregni G, de Braud F, Di Cosimo S. Better together: targeted combination therapies in breast cancer. Semin Oncol. 2015;42(6):887-95. doi: 10.1053/j.seminoncol.2015.09.029.
  36. Treilleux I, Arnedos M, Cropet C, et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol. 2015;26(1):120-5. doi: 10.1093/annonc/mdu497.
  37. Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17(3):279-88. doi: 10.1016/j.neo.2015.01.005.
  38. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. New England J Medicine. 2012;367(5):435-44. doi: 10.1056/NEJMoa1201622.
  39. Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30(16):1919-25. doi: 10.1200/JCO.2011.38.1095.
  40. Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus Anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33(32):3781-7. doi: 10.1200/JCO.2015.61.5831.
  41. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98(2):229-38. doi: 10.1002/cncr.11468.
  42. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3.
  43. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist. 2015;20(3):270-8. doi: 10.1634/theoncologist.2013-0445.
  44. Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930-6. doi: 10.1200/JCO.2014.58.3401.
  45. Burnett AF, Bahador A, Amezcua C. Anastrazole, an aramatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometriel cancer: a report of two cases susccesfuly treated without hysterectomy. Gynecol Oncol. 2004;94(3):832-4. doi: 10.1016/j.ygyno.2004.06.004.
  46. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-1744.
  47. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14(2):357-361.
  48. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19(2):364-367.
  49. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):4-9. doi: 10.1016/j.ygyno.2003.09.018.
  50. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10-14. doi: 10.1016/j.ygyno.2003.11.008.
  51. Asbury RF, Brunetto VL, Lee RB, et al. (Gynecologic Oncology Group). Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol. 2002;25(6):557-560. doi: 10.1097/00000421-200212000-00004.
  52. Landreat V, Paillocher N, Catala L, et al. Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases. Anticancer Res. 2008;28(5B):2869-74.
  53. Sylvestre VT, Dunton CJ. Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review. Horm Cancer. 2010; 1(2): 112-5. doi: 10.1007/s12672-010-0007-9.
  54. Shoji K, Oda K, Nakagawa S, et al. Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. Med Oncol. 2011;28(3):771-4. doi: 10.1007/s12032-010-9511-6.
  55. Akashi D, Todo Y, Shimada C, et al. Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report. Jpn J Clin Oncol. 2013;43(11):1145-9. doi: 10.1093/jjco/hyt142.

Copyright (c) 2016 Fadeeva E.P., Lisyanskaya A.S., Manikhas G.M., Glushakov R.I., Tapilskaya N.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies